文献速递骨质疏松与代谢性骨病

2型糖尿病患者C肽水平与骨密度的关联

Association of C-peptide level with bone mineral density in type 2 diabetes mellitus.
PubMed 文献 · Osteoporos Int · 2023-05-19

本研究纳入530例2型糖尿病患者,按空腹C肽三分位分组,采用双能X线吸收法测骨密度、FRAX评估10年骨折概率。整体上空腹C肽与骨密度及骨折风险无显著线性关系;但在空腹C肽≤1.14 ng/ml组,空腹C肽与全身、腰椎、股骨颈骨密度正相关,与骨折风险负相关。

要点

  • 2型糖尿病患者整体空腹C肽与骨密度、骨折风险无显著线性关系。
  • 空腹C肽≤1.14 ng/ml组中,空腹C肽与全身、腰椎、股骨颈骨密度正相关。
  • 该组中空腹C肽与骨折风险及骨质疏松性骨折史负相关,为独立影响因素。

核心结论

  • 2型糖尿病患者空腹C肽水平与骨密度或骨折风险无显著线性关系。
  • 在空腹C肽≤1.14 ng/ml组,空腹C肽与全身、腰椎、股骨颈骨密度正相关,与骨折风险负相关,且为骨密度和骨折风险的独立影响因素。
  • 作者认为空腹C肽可能预测部分2型糖尿病患者的骨质疏松或骨折风险,具有一定临床价值。

研究设计与样本

  • 纳入530例2型糖尿病患者,按空腹C肽三分位分为三组并收集临床资料。
  • 采用双能X线吸收法(DXA)测量骨密度,采用校正的骨折风险评估工具(FRAX)评估10年主要骨质疏松性骨折(MOF)和髋部骨折(HF)概率。

主要发现

  • 在空腹C肽≤1.14 ng/ml组,空腹C肽与全身、腰椎、股骨颈骨密度正相关,与骨折风险及骨质疏松性骨折史负相关。
  • 在1.14<空腹C肽≤1.73 ng/ml组和空腹C肽>1.73 ng/ml组,空腹C肽与骨密度、骨折风险及骨质疏松性骨折史均无相关性。
  • 在空腹C肽≤1.14 ng/ml组,空腹C肽是影响骨密度和骨折风险的独立因素。

关键数值与推荐

  • 分组阈值为空腹C肽≤1.14 ng/ml、1.14<空腹C肽≤1.73 ng/ml、空腹C肽>1.73 ng/ml。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: This study revealed that there was no significant linear relationship between fasting C-peptide (FCP) level and bone mineral density (BMD) or fracture risk in type 2 diabetes mellitus (T2DM) patients. However, in the FCP ≤ 1.14 ng/ml group, FCP is positively correlated with whole body (WB), lumbar spine (LS), and femoral neck (FN) BMD and negatively correlated with fracture risk. PURPOSE: To explore the relationship between C-peptide and BMD and fracture risk in T2DM patients. METHODS: 530 T2DM patients were enrolled and divided into three groups by FCP tertiles, and the clinical data were collected. BMD was measured by dual-energy X-ray absorptiometry (DXA). The 10-year probability of major osteoporotic fractures (MOFs) and hip fractures (HFs) was evaluated by adjusted fracture risk assessment tool (FRAX). RESULTS: In the FCP ≤ 1.14 ng/ml group, FCP level was positively correlated with WB, LS, and FN BMD, while FCP was negatively correlated with fracture risk and osteoporotic fracture history. However, FCP was not correlated with BMD and fracture risk and osteoporotic fracture history in the 1.14 < FCP ≤ 1.73 ng/ml and FCP > 1.73 ng/ml groups. The study has shown that FCP was an independent factor influencing BMD and fracture risk in the FCP ≤ 1.14 ng/ml group. CONCLUSIONS: There is no significant linear relationship between FCP level and BMD or fracture risk in T2DM patients. In the FCP ≤ 1.14 ng/ml group, FCP is positively correlated with WB, LS, and FN BMD and negatively correlated with fracture risk, and FCP is an independent influencing factor of BMD and fracture risk. The findings suggest that FCP may predict the risk of osteoporosis or fracture in some T2DM patients, which has a certain clinical value.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Yang H, Bai J, Li L, et al. Association of C-peptide level with bone mineral density in type 2 diabetes mellitus. Osteoporos Int. 2023. PMID: 37204453. doi:10.1007/s00198-023-06785-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。